{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:13:56Z","timestamp":1792638836887,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.breast.2025.104690","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T23:49:29Z","timestamp":1767397769000},"page":"104690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Genomic landscape of metastatic breast cancers in young adults: a liquid biopsy analysis of women aged 20\u201340 years"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1798-6596","authenticated-orcid":false,"given":"Ernest","family":"Diab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Roussel-Simonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Dixon-Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Spata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauriane","family":"Minot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Xu-Vuillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Mosele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Grinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Viansone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayma","family":"Bousrih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Zeghondy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Ben Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Nicotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bayle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pistilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Rassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2025.104690_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105553","article-title":"The rising tides of cancers among young adults","volume":"10","author":"Andr\u00e9","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2025.104690_bib2","article-title":"Global Incidence of early-onset cancers rose 80% from 1990 to 2019","author":"Smith","year":"2023","journal-title":"Dermatology Advisor"},{"key":"10.1016\/j.breast.2025.104690_bib3","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(17)30677-0","article-title":"Cancer incidence and mortality among young adults aged 20\u201339 years worldwide in 2012: a population-based study","volume":"18","author":"Fidler","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104690_bib4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amepre.2016.07.039","article-title":"Burden of cancer by race and ethnicity according to disability-adjusted life years","volume":"51","author":"Lortet-Tieulent","year":"2016","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.breast.2025.104690_bib5","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/j.breast.2013.07.034","article-title":"Management of breast cancer in very young women","volume":"22","author":"Freedman","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.breast.2025.104690_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100096","article-title":"Adolescents and young adults (AYA) with cancer: a position paper from the AYA working group of the European society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)","volume":"6","author":"Ferrari","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2025.104690_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.breast.2023.06.001","article-title":"Does age affect outcome with breast cancer?","volume":"70","author":"B Jackson","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.breast.2025.104690_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918776923","article-title":"Should age impact breast cancer management in young women? Fine tuning of treatment guidelines","volume":"10","author":"Suter","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.breast.2025.104690_bib9","article-title":"Early-onset cancers: biological bases and clinical implications","volume":"5","author":"Mauri","year":"2024","journal-title":"CR Med"},{"key":"10.1016\/j.breast.2025.104690_bib10","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.breast.2025.104690_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.breast.2021.12.006","article-title":"The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: a U.S. SEER database analysis","volume":"61","author":"Kim","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.breast.2025.104690_bib13","first-page":"145","article-title":"Dedicated centres and multinational platforms to improve patient care and address early-onset cancers","volume":"25","author":"Ben-Aharon","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.breast.2025.104690_bib14","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/jnci\/djt134","article-title":"Prospective observational study of breast cancer treatment outcomes for UK women aged 18\u201340 years at diagnosis: the POSH study","volume":"105","author":"Copson","year":"2013","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"10.1016\/j.breast.2025.104690_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10414-x","article-title":"The impact of young age for prognosis by subtype in women with early breast cancer","volume":"7","author":"Lian","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.breast.2025.104690_bib16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jamcollsurg.2008.12.001","article-title":"Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease","volume":"208","author":"Gnerlich","year":"2009","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.breast.2025.104690_bib17","article-title":"Comparison of clinicopathological features and treatments between young (\u226440 years) and older (>40 years) female breast cancer patients in west China: a retrospective, epidemiological, multicenter, case only study","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.breast.2025.104690_bib18","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1245\/s10434-019-07653-9","article-title":"Adolescents and young adults with breast cancer have more aggressive disease and treatment than patients in their forties","volume":"26","author":"Murphy","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2025.104690_bib19","doi-asserted-by":"crossref","first-page":"R55","DOI":"10.1186\/bcr3156","article-title":"Occurrence of breast cancer subtypes in adolescent and young adult women","volume":"14","author":"Keegan","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2025.104690_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdf039","article-title":"Very young women (<35 years) with operable breast cancer: features of disease at presentation","volume":"13","author":"Colleoni","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104690_bib21","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-Negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104690_bib22","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2025.104690_bib23","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor\u2013positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2025.104690_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","article-title":"OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"184","author":"Robson","year":"2023","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.breast.2025.104690_bib25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2025.104690_bib26","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO precision medicine working group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104690_bib27","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for Clinical Actionability of molecular targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104690_bib28","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","article-title":"Genomic characterization of metastatic breast cancers","volume":"569","author":"Bertucci","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.breast.2025.104690_bib29","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12916-015-0504-3","article-title":"Genomic aberrations in young and elderly breast cancer patients","volume":"13","author":"Azim","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.breast.2025.104690_bib30","first-page":"3324","article-title":"Young Age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression","volume":"26","author":"Anders","year":"2008","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.breast.2025.104690_bib31","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-11-2599","article-title":"Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling","volume":"18","author":"Azim","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2025.104690_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001373","article-title":"Age-specific differences in oncogenic pathway deregulation seen in human breast tumors","volume":"3","author":"Anders","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.breast.2025.104690_bib33","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.clbc.2024.07.008","article-title":"The genomic landscape of breast cancer in young and older women","volume":"24","author":"Heeke","year":"2024","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2025.104690_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103716","article-title":"Precision oncology in patients with breast cancer: towards a \u2018screen and characterize\u2019 approach","volume":"9","author":"Rassy","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2025.104690_bib35","series-title":"Evaluating liquid biopsy as a surrogate for germline testing in metastatic breast cancer: concordance and discordance Analysis in the STING Program","author":"Spata","year":"2025"},{"key":"10.1016\/j.breast.2025.104690_bib36","doi-asserted-by":"crossref","first-page":"GS4","DOI":"10.1158\/1538-7445.SABCS21-GS4-08","article-title":"Abstract GS4-08: comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance","volume":"82","author":"Safonov","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2025.104690_bib37","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/jnci\/djm207","article-title":"Molecular basis for Estrogen receptor \u03b1 deficiency in BRCA1-Linked breast cancer","volume":"99","author":"Hosey","year":"2007","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"10.1016\/j.breast.2025.104690_bib38","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/onc.2010.603","article-title":"Targeting the Akt\/mTOR pathway in Brca1-deficient cancers","volume":"30","author":"Xiang","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.breast.2025.104690_bib39","doi-asserted-by":"crossref","first-page":"10040","DOI":"10.1158\/0008-5472.CAN-08-3009","article-title":"Negative regulation of AKT activation by BRCA1","volume":"68","author":"Xiang","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2025.104690_bib40","doi-asserted-by":"crossref","first-page":"5854","DOI":"10.1038\/sj.onc.1209872","article-title":"The role of BRCA1 in transcriptional regulation and cell cycle control","volume":"25","author":"Mullan","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.breast.2025.104690_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac7551","article-title":"Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer","volume":"7","author":"Schiavon","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.breast.2025.104690_bib42","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41568-018-0001-z","article-title":"Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance","volume":"18","author":"Katzenellenbogen","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.breast.2025.104690_bib43","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-21-3276","article-title":"Clinical significance of PIK3CA and ESR1 mutations in circulating tumor DNA: analysis from the MONARCH 2 study of abemaciclib plus fulvestrant","volume":"28","author":"Tolaney","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2025.104690_bib44","first-page":"2961","article-title":"Plasma ESR1 mutations and the treatment of Estrogen receptor\u2013positive advanced breast cancer","volume":"34","author":"Fribbens","year":"2016","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.breast.2025.104690_bib45","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1158\/1078-0432.CCR-24-2307","article-title":"ESR1 Y537S and D538G mutations drive resistance to CDK4\/6 inhibitors in Estrogen receptor\u2013positive breast cancer","volume":"31","author":"Lin","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2025.104690_bib46","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","article-title":"Therapeutic resistance to anti-oestrogen therapy in breast cancer","volume":"23","author":"Will","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.breast.2025.104690_bib47","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-Mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2025.104690_bib48","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104690_bib49","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, hormone receptor\u2013positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2025.104690_bib50","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s12282-017-0812-x","article-title":"Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K\/Akt\/mTOR in estrogen receptor-positive, HER2-negative breast cancer","volume":"25","author":"Araki","year":"2018","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2025.104690_bib51","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3390\/cancers11091242","article-title":"The PI3K\/AKT\/mTOR and CDK4\/6 pathways in Endocrine resistant HR+\/HER2\u2212 metastatic breast cancer: biological mechanisms and new treatments","volume":"11","author":"Presti","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2025.104690_bib52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13058-020-01284-9","article-title":"Frequency and spectrum of PIK3CA somatic mutations in breast cancer","volume":"22","author":"Mart\u00ednez-S\u00e1ez","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2025.104690_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw9032","article-title":"Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors","author":"Vasan","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.breast.2025.104690_bib54","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s13058-014-0406-x","article-title":"PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors","volume":"16","author":"Lehmann","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2025.104690_bib55","doi-asserted-by":"crossref","first-page":"S1212","DOI":"10.1016\/j.annonc.2024.08.2257","article-title":"LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): the CAPItello-290 phase III trial","volume":"35","author":"Schmid","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104690_bib56","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.3390\/ijms21134579","article-title":"Biomarkers in triple-negative breast cancer: state-of-the-art and future perspectives","volume":"21","author":"Cocco","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.breast.2025.104690_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005852","article-title":"BRCA1 deficiency in mature CD8+ T lymphocytes impairs antitumor immunity","volume":"11","author":"Wu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.breast.2025.104690_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal4922","article-title":"Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer","volume":"9","author":"Nolan","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.breast.2025.104690_bib59","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/ijc.22915","article-title":"Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility","volume":"121","author":"Barwell","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2025.104690_bib60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/76950","article-title":"Brca1 required for T cell lineage development but not TCR loci rearrangement","volume":"1","author":"Mak","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.breast.2025.104690_bib61","article-title":"Liquid biopsy to identify actionable genomic alterations","volume":"978\u2013997","author":"Ou","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.breast.2025.104690_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101253","article-title":"29P prevalence of high tumor mutational burden (TMB) in patients with metastatic breast cancer (mBC) assessed by liquid biopsy (LB)","volume":"8","author":"Ribeiro","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2025.104690_bib64","unstructured":"Association between biomarkers and clinical outcomes of pembrolizumab monotherapy in patients with metastatic triple-negative breast cancer: KEYNOTE-086 exploratory analysis | JCO Precision Oncology. https:\/\/ascopubs.org\/doi\/full\/10.1200\/PO.22.00317."},{"key":"10.1016\/j.breast.2025.104690_bib65","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41597-023-02253-5","article-title":"Global trends and forecasts of breast cancer incidence and deaths","volume":"10","author":"Xu","year":"2023","journal-title":"Sci Data"},{"key":"10.1016\/j.breast.2025.104690_bib66","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","article-title":"Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing","volume":"127","author":"Neumann","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2025.104690_bib67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10549-024-07535-z","article-title":"Molecular tumor board in patients with metastatic breast cancer","volume":"210","author":"Boscolo Bielo","year":"2025","journal-title":"Breast Cancer Res Treat"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625009099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625009099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:08:28Z","timestamp":1770998908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625009099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":65,"alternative-id":["S0960977625009099"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104690","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic landscape of metastatic breast cancers in young adults: a liquid biopsy analysis of women aged 20\u201340 years","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104690"}}